India: Do we need Patent Term Extension and Non-Patent Exclusivities for Pharmaceuticals?
India, though in a phase of rapid economic development, still has the bane of poverty. In this country, around 22% of the population is Below the Poverty Line [1], and hence most of the nation’s policies are oriented towards the poor. India’s IP Policy is no different, as the IP legislature in India is mostly […]
First Symposium of IIPRD in 2017
After successfully conducting several symposiums in 2016, IIPRD is coming up with one-day seminar on software and electronics patent portfolio with focus on preliminary preparation, prosecution, and litigation in India and US. While the programme is being organized in Pune on February 23, the one in Bengaluru will be hosted February 24. The seminar is […]
Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention […]
A Primer to Patent Application Drafting with special emphasis on standard practise(s) before the Indian Patent Office
An enforceable Patent being the key to effective Commercialization/Out-Licensing of any technology needs to be drafted well. No matter how good a technology is, if the description of the technical subject matter of a Patent is not enabling or fails to disclose all necessary embodiments, and in case the claims are narrowly drafted and do […]
PATENT INFRINGMENT SUIT BY DOLBY AGAINST OPPO AND VIVO
Anjana Mohan, an intern at Khurana & Khurana, Advocates and IP Attorneys deals with the updates in the Patent Litigation between Dolby International and two Smartphone companies Oppo and Vivo over the patented technology by Dolby. Dolby filed suits vide Suit no CS(COMM) 1425/2016 and CS(COMM) 1426/2016 against various parties including the two major Chinese […]
Merk’s patent valid but Teva’s Nasonex generic non-infringing
In Merck Sharp & Dohme Corp. (hereinafter referred to be as “Merck”) v. Teva Pharms. United States, Inc. (hereinafter referred to be as “Teva”) decided on November 16, 2016, Teva’s application of Abbreviated New Drug Application (hereinafter referred to as “ANDA”) no. 205149 had triggered Merck to file infringement suit against Teva in respect of […]
Simplified account of Design Registration in India
This article is intended with covering the basic FAQs about Design registration in India. For the sake of better focusing, the format of questions and answers has been adopted. Industrial Designs are protected by different laws in different countries, i.e. some countries choose to go for Patent Registration and some go for specialized systems. Unlike […]
Simplified account of Copyright Registration in India
This article is intended with covering the basic FAQs about Copyright registration in India. For the sake of better focusing, format of questions and answers has been adopted. What is Copyright? Copyright is a right given by the law to creators of literary, dramatic, musical and artistic works and producers of cinematograph films and sound […]
Simplified account of Trademark Registration in India
We had written an article giving a simplified account of Patenting procedures in India to enable readers who are new to the Patents. A similar attempt is being made here to provide answers to the Trademark FAQs so as to enable readers who are new to the Trademark. What is a trademark? What is the […]
Hetero’s Subsidiaries not infringing Roxane’s patent on PhosLo
In Roxane Laboratories, Inc. (hereinafter referred to be as “Roxane”) v. Camber Pharmaceuticals Inc., et al. (hereinafter referred to as “Camber”) decided by United States Court of Appeals for the Federal Circuit on November 17, 2016, Roxane had appealed against decision of district court in an infringement suit against Camber and Invagen Pharmaceuticals Inc (collectively […]